## **SwissCaRe**











| Patient hospital label  | Hospital patient identification number |  |   |  |  |
|---|--|--|---|--|--|
|   | Surname                                |  | Date of birth<br>dd.mm.yyyy   |  |  |
|   | First name                             |  | Biological sex<br>O f O m   |  |  |
| Baseline characterist   | ics                                    |  |   |  |  |
| cvRF  ○ None  □ Arterial hypertension (on treati □ Diabetes requiring medication  | •                                      | <ul><li>□ Dyslipidemia (on stat</li><li>□ Smoking (active)</li><li>□ Family history</li><li>○ cvRF unknown / not one</li></ul>   | in or LDL-C>2.6mmol/L)  |  |  |
| O None O Norm ☐ Prior PCI (with or without stents) O Mild ☐ Prior CABG O Mod  |  | By laevugram or non-invasive image mal (50-70%) Olly reduced (40-49%) derately reduced (<30-39%) erly reduced (<30%)   | ging test closest to CA) Unknown / not documented   |  |  |
| Out of hospital cardiac arrest O Yes O No   |  | genic shock<br>90 mmHg for 30 min or vasopressor to<br>O No  | o maintain, and lactate > 2 mmol/L)   |  |  |
| Intubated O Yes O No  |  | nical support device(s) of either cardiogenic shock or hig ne □ Impella □ ECMO   | nh-risk PCI)  |  |  |
| Indication  |  |  |   |  |  |
| Indication (only one answer)  O Clinical presentation as ACS O Suspected CAD or suspected of known CAD O Planned valvular heart disease Follow-up after HTX O Heart failure (LVEF < 40%) O Routine follow-up (e.g. after le | e intervention                         | If ACS, please specify (Cardiac count as NSTEMI)  O Unstable angina pectoris (new pectoris, according to Braunw O Non-STEMI O STEMI  If suspected CAD was indicated, Coronary angiography-precee (high-pretest likelihood) O None Treadmill indicating ischemia CCTA with significant stenos Stress MRI with ischemia Stress TTE with ischemia TTE with hypokinesia Nuclear test with ischemia | w or progressive angina vald definition)  please choose the following ding test(s) suggesting CAD  a (or other exercise stress tests) |  |  |

## SwissCaRe 2024 Coronary angiography and PCI









| Symptoms if suspected or stable CAD  |                      |  |   |  |
|--|----------------------|--|---|--|
| <b>Dyspnoe</b><br>○ Yes ○ No   |                      |  |   |  |
| Angina pectoris  O Yes CCS OI OII  |                      | <b>ti-anginal drugs</b> (prior or current, betab<br>cker, long-acting nitrate, Ivabradine, Ranol |   |  |
| O No   |                      | Yes O No   | ,   |  |
| STEMI-related refer  | ral times            |  |   |  |
| Date of symptoms onset dd.mm.yyyy  |                      | Time of symptoms onset  hh:mm  | O Symptoms onset unknown / not documented |  |
| Date of hospital entry<br>dd.mm.yyyy   |                      | Time of hospital entry hh:mm   |   |  |
| Date of recanalization<br>dd.mm.yyyy   |                      | Time of recanalization  hh:mm  |   |  |
| Non-STEMI-related referral times   |                      |  |   |  |
| Time between first ECG and   | coronary angiograp   | hy   |   |  |
| O <24 hours O 2  | 24-48 hours C        | ) >48 hours O unknown / not  | t documented                              |  |
| General procedural characteristics   |                      |  |   |  |
| Date of procedure  |                      |  |   |  |
| dd.mm.yyyy   |                      |  |   |  |
| Access (access through which the PCI was finalized)  O Femoral (Radial attempt converted to femoral counts as femoral)  O Radial (Brachial counts as radial) |                      |  |   |  |
| Dose unit O mGycm2 O cGycm2 or uGym2   | Dose (round to whole | e number)  |   |  |

## **SwissCaRe**











## PCI-specific procedural characteristics \_

| O PCI aborted Only complete CTO procedure,   | intracoronary physiology and imaging                        |  |  |  |
|--|---|--|--|--|
| Number of treated lesions (Coronary artery lesion overlapping stents, this counts as one lesion)                                   | n undergoing PCI. If two lesions are covered by two or more |  |  |  |
| Number of treated vessels LM, LAD, LCX, RCA, or graft. If a lesion extends over the main vessel is counted                         | Ver several vessels only treated O Yes O No                 |  |  |  |
| Number of implanted stents Number of used  | drug-eluting balloons Intervention(s) for stent failure     |  |  |  |
|  | O None  |  |  |  |
|  | Restenosis  |  |  |  |
| 070  | Stent thrombosis  |  |  |  |
| CTO procedure Calcium modification   |   |  |  |  |
| (Chronic occlusion presumably > 3 months, Subacute ACS O None ☐ Rotablation presentation excluded) ☐ Cutting balloon ☐ Lithotripsy |   |  |  |  |
| O None O Antegrade O Retrograde  | ☐ Scoring balloon ☐ Orbital atherectomy                     |  |  |  |
| ☐ High-pressure balloon (RBP ≥ 30 atm)   |   |  |  |  |
| Bifurcation Intracoronary physiology   |   |  |  |  |
| O None   |   |  |  |  |
| O 1 stent Intracoronary in   |   |  |  |  |
| O 2 stents O None  | □ IVUS □ OCT  |  |  |  |
| Complication   |   |  |  |  |
| Major complication   |   |  |  |  |
| O None   | ☐ Clinically overt stroke                                   |  |  |  |
| ☐ Emergency open heart surgery   | ☐ Emergency vascular surgery (non-cardiac)                  |  |  |  |
| ☐ Procedural death   | ☐ Pericardial tamponade                                     |  |  |  |
| Prescribed medication  |   |  |  |  |
| Prescribed medication at the time of discharge from CathLab, including previously prescribed medication that will be continued     |   |  |  |  |
| Antithrombotic medication  |   |  |  |  |
| ☐ ASA ☐ P2Y12 inhibitor  | □ N/OAC   |  |  |  |
| If P2Y12 inhibitor, specify  | Statin therapy  |  |  |  |
| O Clopidogrel O Ticagrelor   | O None  |  |  |  |
| O Prasugrel O Other  | O Low-intensity (or moderate-intensity)                     |  |  |  |
|  | O High-intensity (Rosuvastatin ≥ 20mg, Atorvastatin ≥ 40mg) |  |  |  |
| If dual antiplatelet therapy, specify duration (select closest answer)   |   |  |  |  |
| O <1 month   | O 6 months  |  |  |  |
| O 1 month  | O 12 months   |  |  |  |
| O 3 months   | O >12 months  |  |  |  |
| If triple antithrombotic therapy, specify duration (select closest answer)   |   |  |  |  |
| O <1 week  | O 3 months  |  |  |  |
| O 1 month  | O 6 months  |  |  |  |